New hope for kids with tough cancer: drug may keep neuroblastoma at bay

NCT ID NCT07278674

Ongoing Disease control Sponsor: Shanghai Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug eflornithine, taken as a pill after immunotherapy, can help prevent high-risk neuroblastoma from coming back in children. Twenty children under 18 who have completed standard treatment will take eflornithine for maintenance. Researchers will track how long they stay cancer-free and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eflornithine
What this could lead to: If it works, this could help prevent relapse and improve survival in children with high-risk neuroblastoma after standard treatment.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply broadly. Side effects from eflornithine are possible and will be monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK NEUROBLASTOMA

Contacts and locations

Locations

Ruijin Hospital Hainan Branch, affiliated with Shanghai Jiao Tong University School of Medicine and Children's Hospital of Shanghai, affiliated with Shanghai Jiao Tong University School of Medicine

Hainan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.